Longeveron Inc (LGVN) 宣布,其针对老年衰弱患者的2B期临床试验取得积极成果。研究数据显示,采用干细胞疗法后,患者的整体健康状况获得显著改善。这一重要发现已发表于国际权威期刊《Cell Stem Cell》。
Longeveron Inc (LGVN) 宣布,其针对老年衰弱患者的2B期临床试验取得积极成果。研究数据显示,采用干细胞疗法后,患者的整体健康状况获得显著改善。这一重要发现已发表于国际权威期刊《Cell Stem Cell》。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.